三七口服液通过抑制HIF-1α/PKM2/糖酵解通路改善慢性肾脏病肾纤维化
三七口服液(SQ)是临床上广泛用于治疗慢性肾脏病(CKD)的中成药,既往研究证实其抗肾纤维化作用但机制不明。本研究在5/6肾切除大鼠和TGF-β1诱导的NRK-49F细胞中,从能量代谢角度探究SQ的肾脏保护机制。结果表明SQ通过靶向HIF-1α调控PKM2激活的糖酵解,抑制成纤维细胞活化,从而改善CKD肾纤维化。
要点
- SQ可改善5/6Nx大鼠肾功能,降低肾脏乳酸和丙酮酸水平。
- SQ抑制成纤维细胞增殖与糖酵解,下调HIF-1α、PKM2、HK2及纤维化标志物。
- HIF-1α过表达可逆转SQ效应,提示HIF-1α/PKM2/糖酵解通路为其作用靶点。
核心结论
- SQ通过靶向HIF-1α调控PKM2激活的糖酵解,抑制成纤维细胞活化,进而改善CKD肾纤维化。
研究设计与样本
- 体内实验采用5/6肾切除(5/6Nx)大鼠模型评估SQ对肾脏的疗效。
- 体外实验采用TGF-β1诱导的NRK-49F细胞,并通过沉默或过表达HIF-1α基因探究通路作用。
主要发现
- 在5/6Nx大鼠中,SQ改善肾功能、减轻肾损伤,降低肾脏匀浆乳酸和丙酮酸水平。
- SQ降低CKD大鼠肾组织中HIF-1α、PKM2、HK2、α-SMA、波形蛋白、I型胶原和PCNA表达。
- 体外实验中SQ抑制NRK-49F细胞增殖、糖酵解及TGF-β1诱导的HIF-1α、PKM2表达。
- 过表达HIF-1α促进TGF-β1诱导的NRK-49F细胞乳酸和丙酮酸分泌,该变化被SQ或沉默HIF-1α逆转。
- 过表达HIF-1α进一步诱导PKM2表达升高,SQ干预可降低PKM2表达;沉默HIF-1α后PKM2表达亦受抑制,此时SQ无效。
临床怎么用
- 三七口服液作为临床用于CKD的中成药,其抗肾纤维化作用可能与抑制成纤维细胞HIF-1α/PKM2/糖酵解通路相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Sanqi oral solution (SQ) is a traditional Chinese patent medicine, widely used to treat chronic kidney diseases (CKD) in the clinic in China. Previous studies have confirmed its anti-renal fibrosis effect, but the specific pharmacological mechanism is still unclear. AIM OF THE STUDY: Focusing on energy metabolism in fibroblasts, the renoprotective mechanism of SQ was investigated in vitro and in vivo. METHODS: Firstly, the fingerprint of SQ was constructed and its elementary chemical composition was analyzed. In the 5/6Nx rats experiment, the efficacy of SQ on the kidney was evaluated by detecting serum and urine biochemical indexes and pathological staining of renal tissues. Lactic acid and pyruvic acid levels in serum and renal tissues were detected. PCNA protein expression in kidney tissue was detected by immunofluorescence assay and Western blot. Expression levels of HIF-1α, PKM2 and HK2 were determined by immunohistochemistry, Western blot or RT-qPCR assay. In addition, the effect of SQ intervention on cell proliferation and glycolysis was evaluated in TGF-β1-induced NRK-49F cells, and the role of SQ exposure and HIF-1α/PKM2/glycolysis pathway were further investigated by silencing and overexpressing HIF-1α gene in NRK-49F cells. RESULTS: In 5/6 Nx rats, SQ effectively improved renal function and treated renal injury. It reduced the levels of lactic acid and pyruvic acid in kidney homogenates from CKD rats and decreased the expression levels of HIF-1α, PKM2, HK2, α-SMA, vimentin, collagen I and PCNA in kidney tissues. Similar results were observed in vitro. SQ inhibited NRK-49F cell proliferation, glycolysis and the expression levels of HIF-1α, PKM2 induced by TGF-β1. Furthermore, we established NRK-49F cells transfected with siRNA or pDNA to silence or overexpress the HIF-1α gene. Overexpression of HIF-1α promoted cellular secretion of lactic acid and pyruvic acid in TGF-β1-induced NRK-49F cells, however, this change was reversed by intervention with SQ or silencing the HIF-1α gene. Overexpression of HIF-1α can further induce increased PKM2 expression, while SQ intervention can reduce PKM2 expression. Moreover, PKM2 expression was also inhibited after silencing HIF-1α gene, and SQ was not effective even when given. CONCLUSION: The mechanism of action of SQ was explored from the perspective of energy metabolism, and it was found to regulate PKM2-activated glycolysis, inhibit fibroblast activation, and further ameliorate renal fibrosis in CKD by targeting HIF-1α.
引用
- Hu D, Wang L, Zhang Y, et al. Sanqi oral solution ameliorates renal fibrosis by suppressing fibroblast activation via HIF-1α/PKM2/glycolysis pathway in chronic kidney disease. J Ethnopharmacol. 2024. PMID: 39121930. doi:10.1016/j.jep.2024.118679
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。